Member Info for crumbs

Yeah... but I'm waiting on £30 a share so will probably have to hold to ooh 2022 :p
Scancell capable of having a $20 billion mcap by 2022? ... if the moditope mechanism works exceptionally well ... absolutely!.... As it would be a platform capable of targeting and eradicating most cancer types in most patients.

Nice one Cars really hope you get your reward (as I'll get mine then too lol) I'm down for a little Thursday nibble myself .... There are many possible coming events here and I too think the BioNtech TCR deal is looking good....appointment of Sam Paxton to spearhead the 'new TCR therapeutics'.... signs are there and as I have previously posted the lowest upfront deal of that type in the TCR sphere is for $8million upfront per target with milestones up to $200 million... that would put a 4p raising right out the window :)

Yup, that is about it...

BioNtech expected to IPO for $5 billion?... what is the math behind that?

Ruck... can you explain how Juno sold for $9 billion... it had no commercial products?
And Kite for $11 billion?... no commercial products?
show us the math

No you are supposed to say... this NEVER going to be zero :p

Ok £30 is verrrry out there optimistic and comes from success on everything ...ImmunoBody.. Glycans but most of all that the mechanism of moditope indeed works as well in trial as it does in humanised mouse models and has shown itself to work in donated human bloods from both healthy and cancer patient donors.... You would be talking about moditope creating its own market... as innanco said it would be moditope going up against gravediggers .... so £30 impossible... I'm talking about a platform that could be a pharma all by itself...

Hope so... I don't know if there are any other CRUK deal trial equivalents we can compare it to?..... you would think the nano delivery would have been agreed on by now too.

I do think they could do more too TF... we were promised a new website at AGM... but no new website has appeared I get they concentrate on the really important stuff which is the lab progress and getting that into the clinic but as a listed company dependant on investment funding they could do a lot better...of course they may well know exactly how the money is coming and have no worries whatsoever ( you would think they will for sure know about TCR deal likelihood by now) but if so they are not translating that back to us very well :) ...

Have always been frustrating and hampered by delays here... however! SCIB1 combo only waits for one thing now FDA greenlight.... modi1 is and possibly has finished tox testing...the formulation and addition of the amplivant adjuvant are all done so for modi1 everything is on track however that trial will need additional funding...scancell are in moditope partnership talks and have been for at least a year.... BioNtech (our most known deal hope) the research collab comes to an end H1 2019 so anytime now... scancell tell us the collab is going well and the relationship is 'solid' ... and along side the collab they have been working hard to secure that deal.... so yeah a quiet period but plenty going on that we will hear about when we do... oh SCIB2 progress into trial for that we wait on CRUK but again scancell tell us that relationship is 'solid'

You forgot huge placing at 4p :)))... you can't ride a horse with no balance!

They do answer emails though :)

There are no fundamental events differing to what is reported in RNS's for sp action so why would scancell comment?

Sure is taking a beating... I'm looking at ending up with 200k now... considering this is a zero to possible £30 quid a share end game I'm willing to take the risk ....'new TCR therapeutics'

Yeah but so far no...

Someone is bound to run on the pitch to deliver a blow!

Yeah only one way now till some positive news... I might actually catch your holding up yet :)

I'm not sure if it is more miserable outside or in here! :))

Scancells story is not written yet meantime I think it is fine to have all kinds of opinions and views but best not to get too personal or AGM will need a bigger venue so the seats can be placed at huge distances from each other lol

I'll check down the back of my sofa..... .. no not there

It is significant Lindy has now brought all her techs into scancell and shows she must believe it to be the best way forwards in getting her techs into the clinic... We have heard very little since the bringing in of Glycan MABs and the associated platform tech but certainly another piece of IP totally unvalued - yet!....

'Commercial and economic impact
Nottingham University Therapeutic Antibody centre (NUTAC) has been established to develop and licence monoclonal antibodies (mAbs). Professor Durrant has had success with this process through her spin out company Scancell Ltd using external investment. The current business model is that NUTAC would develop and licence new mAbs using University (£500k)/grant (£500k) income so that all future income flows to the University will enable development of further mAbs. We have produced four mouse mAbs which show selective in vitro and in vivo tumour killing. Chimerisation of those mAbs to human IgG1 mAbs coincided with a reduction in potency. The current grant is designed to confirm the key residues in the mouse mAbs that are required for this increased potency and to transfer it to the human mAbs. This will not only allow us to produce 3 novel human mAbs for licensing to the Biotechnology/Pharmaceutical industry but could form a platform to improve the efficacy of all human mAbs.The top two lead mAbs, FG27 and FG88, could potentially treat 214,500 and 421,500 patients per annum based upon the % of tumours that express the target antigen. These are patients who currently have failed all other therapies and die of their disease. If we assume market penetration of 50% and a treatment price of £10,000 per patient this is a potential market of £1-2 billion.

Patient Benefit
Our mAbs can be used in the treatment of a wide range of cancer patients. As they not only directly kill tumours but initiative immune responses they should confer similar survival benefits to the new checkpoinhibitors which are currently curing 20-50% of advanced melanoma patients. If our mAbs are used to treat over 300,000 patients per annum and a conservative 20% are cured this could result in saving over 60,000 lives per annum. '

Is getting an airing this week... presenting moditope in a London conference on Friday:

http://www.mnmconferences.com/3rd-Annual-MarketsandMarkets-Next-Gen%20Immuno-Oncology-Congress/